Emotra AB (publ) Interim report January 1 – June 30, 2019
The Board and CEO of Emotra AB (publ) hereby present [...]
Emotra: New focus areas and more research collaborations
Emotra AB (“Emotra”) has had an eventful spring. New data [...]
Communiqué from the Annual General Meeting of EMOTRA AB (publ)
The Annual General Meeting of EMOTRA AB (publ) was held [...]
Emotra AB (publ) Interim report January 1 – March 31, 2019
The Board and CEO of Emotra AB (publ) hereby present [...]
EDOR® Test Identifies Patients with a Higher Risk of Depression Relapse
Emotra has previously announced that new research results have indicated [...]
Emotra is granted a patent in the USA
The US will be one of Emotra’s priority markets in [...]
Documents for the Annual General Meeting now available
Emotra AB (publ) (“Emotra”) today announces that the Company’s Annual [...]
Notice of Annual General Meeting of shareholders in Emotra AB (publ)
Notice is hereby given that the Annual General Meeting of [...]
Emotra: Comments on questions about EUDOR-A
Emotra has learnt that communications from an individual researcher have [...]
Emotra AB (publ) Year-end report January 1 – December 31, 2018
The Board and CEO of Emotra AB herewith present the [...]